Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Hemant Murthy

BMT · Mayo Clinic Florida

View

Dr. Talal Hilal

Lymphoma · Mayo Clinic College of Medicine

View

Dr. Midhun Malla

GI Oncology · UAB

View

Dr. Saad Usmani

Myeloma · MSK

View

Dr. Kamal Menghrajani

Leukemia · MGH

View

Dr. Hope Rugo

Breast Oncology · City of Hope

View

Dr. Gideon Dosunmu

GI Oncology · Emory Hospital Midtown

View

Dr. Pavlos Msaouel

GU Oncology · MD Anderson Cancer Center

View

Dr. Virginia Borges

Breast Oncology · CU Anschutz Medical Campus

View

Dr. Naval Daver

Leukemia · MD Anderson Cancer Center

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    GSDr. Gunjan Shah

    Dr. Gunjan Shah

    Hematology & Oncology · Bone Marrow Transplant (BMT)
    Memorial Sloan Kettering Cancer Center
    gunjan

    Research

    Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy

    2025

    Via Haematologica

    Research

    Dynamics of Immune Reconstitution and Impact on Outcomes across CAR-T Cell Products in Large B-cell Lymphoma

    2025

    Via Blood Cancer Discovery

    Research

    Results From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell Lymphoma

    2025

    Via Journal of Clinical Oncology

    Research

    Treatment failure patterns in early versus late introduction of CAR T-cell therapy in large B-cell lymphoma

    2025

    Via Bone Marrow Transplantation

    Research

    CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration

    2025

    Via The New England Journal of Medicine

    Research

    Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry

    2025

    Via Journal for Immunotherapy of Cancer

    Research

    Restarting teclistamab and talquetamab after prolonged dose delay may not require re-step-up dosing

    2025

    Via Blood Advances

    Research

    An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma

    2025

    Via Nature Medicine

    Research

    Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma

    2025

    Via Blood Advances

    Research

    CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma

    2025

    Via Blood Cancer Journal

    Research

    T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy

    2025

    Via Blood

    Research

    Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma

    2025

    Via Blood Advances

    Research

    Barriers to Chimeric Antigen Receptor T-Cell Therapy

    2025

    Via JAMA Oncology

    Research

    Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: a SEER-Medicare data analysis

    2025

    Via Blood Advances

    Research

    Bone marrow and blood demonstrate distinct immune reconstitution patterns and correlations with relapse posttransplant

    2025

    Via Blood Advances